| Sumitra Shyamsundar, MD | |
|
2041 Georgia Ave Nw, Washington, DC 20060-0001 | |
| (202) 865-6711 | |
| (202) 865-6713 |
| Full Name | Sumitra Shyamsundar |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology |
| Experience | 39 Years |
| Location | 2041 Georgia Ave Nw, Washington, District Of Columbia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659441152 | NPI | - | NPPES |
| 010240727 | Medicaid | VA | |
| 034155500 | Medicaid | DC | |
| 511400400 | Medicaid | MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | MD33666 (District Of Columbia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Howard University Hospital | Washington, DC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Us Anesthesia Partners Of Dc Pc | 7719395888 | 18 |
News Archive
The systematic neglect of culture is the single biggest barrier to advancing the highest attainable standard of health worldwide, say the authors of a major new report on culture and health, led by Professor David Napier, a leading medical anthropologist from University College London (UCL), UK, and published in The Lancet.
Repairing birth defects in the womb. Inserting a tiny laser into the mother's uterus to seal off an abnormal blood flow and save fetal twins. Advancing the science that may allow doctors to deliver cells or DNA to treat sickle cell anemia and other genetic diseases before birth.
A recent Finnish study could pave the way for preventing brain and cardiac ischemia induced by atherosclerosis. Finnish researchers have found that the low-expression variant of fatty acid-binding protein 4 (FABP4), which is particularly common among Finns, reduces the risk of heart attack and stroke.
ThromboGenics NV and co-development partner BioInvent International announce today positive results from their Phase II trial of TB-402. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism (VTE) following orthopaedic surgery.
› Verified 3 days ago
| Entity Name | Howard University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033163597 PECOS PAC ID: 0941109565 Enrollment ID: O20040102000561 |
News Archive
The systematic neglect of culture is the single biggest barrier to advancing the highest attainable standard of health worldwide, say the authors of a major new report on culture and health, led by Professor David Napier, a leading medical anthropologist from University College London (UCL), UK, and published in The Lancet.
Repairing birth defects in the womb. Inserting a tiny laser into the mother's uterus to seal off an abnormal blood flow and save fetal twins. Advancing the science that may allow doctors to deliver cells or DNA to treat sickle cell anemia and other genetic diseases before birth.
A recent Finnish study could pave the way for preventing brain and cardiac ischemia induced by atherosclerosis. Finnish researchers have found that the low-expression variant of fatty acid-binding protein 4 (FABP4), which is particularly common among Finns, reduces the risk of heart attack and stroke.
ThromboGenics NV and co-development partner BioInvent International announce today positive results from their Phase II trial of TB-402. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism (VTE) following orthopaedic surgery.
› Verified 3 days ago
| Entity Name | Us Anesthesia Partners Of Dc Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710598859 PECOS PAC ID: 7719395888 Enrollment ID: O20210412000137 |
News Archive
The systematic neglect of culture is the single biggest barrier to advancing the highest attainable standard of health worldwide, say the authors of a major new report on culture and health, led by Professor David Napier, a leading medical anthropologist from University College London (UCL), UK, and published in The Lancet.
Repairing birth defects in the womb. Inserting a tiny laser into the mother's uterus to seal off an abnormal blood flow and save fetal twins. Advancing the science that may allow doctors to deliver cells or DNA to treat sickle cell anemia and other genetic diseases before birth.
A recent Finnish study could pave the way for preventing brain and cardiac ischemia induced by atherosclerosis. Finnish researchers have found that the low-expression variant of fatty acid-binding protein 4 (FABP4), which is particularly common among Finns, reduces the risk of heart attack and stroke.
ThromboGenics NV and co-development partner BioInvent International announce today positive results from their Phase II trial of TB-402. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism (VTE) following orthopaedic surgery.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sumitra Shyamsundar, MD 2024 Georgia Ave Nw, Washington, DC 20001-3027 Ph: (202) 595-3223 | Sumitra Shyamsundar, MD 2041 Georgia Ave Nw, Washington, DC 20060-0001 Ph: (202) 865-6711 |
News Archive
The systematic neglect of culture is the single biggest barrier to advancing the highest attainable standard of health worldwide, say the authors of a major new report on culture and health, led by Professor David Napier, a leading medical anthropologist from University College London (UCL), UK, and published in The Lancet.
Repairing birth defects in the womb. Inserting a tiny laser into the mother's uterus to seal off an abnormal blood flow and save fetal twins. Advancing the science that may allow doctors to deliver cells or DNA to treat sickle cell anemia and other genetic diseases before birth.
A recent Finnish study could pave the way for preventing brain and cardiac ischemia induced by atherosclerosis. Finnish researchers have found that the low-expression variant of fatty acid-binding protein 4 (FABP4), which is particularly common among Finns, reduces the risk of heart attack and stroke.
ThromboGenics NV and co-development partner BioInvent International announce today positive results from their Phase II trial of TB-402. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism (VTE) following orthopaedic surgery.
› Verified 3 days ago
Dr. Fay Horng, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 110 Irving St Nw, Washington, DC 20010 Phone: 202-877-7504 | |
Dr. Matthew Mueller, DO, MPH Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 110 Irving St Nw, Washington, DC 20010 Phone: 202-877-7000 | |
Dr. Shane Zamani, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 900 23rd St Nw, Washington, DC 20037 Phone: 202-715-4750 | |
Dr. Thomas Edward Borsari, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 50 Irving St Nw, Dept Of Anesthesiology, Washington, DC 20422 Phone: 202-745-8000 | |
Alexis Lambros, CAA Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 111 Michigan Ave Nw, Washington, DC 20010 Phone: 202-476-2025 | |
Susan Verghese, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 111 Michigan Ave Nw, Washington, DC 20010 Phone: 202-884-2025 | |
Joan Threlfall, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3800 Reservoir Rd Nw, Washington, DC 20007 Phone: 202-444-8640 |